Kymera, Sanofi sign potential $2bn deal to develop IRAK4 protein degraders
IRAK4 is a protein involved in inflammation mediated by the activation of toll-like receptors (TLRs) and IL-1 receptors…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
10 Jul 20
IRAK4 is a protein involved in inflammation mediated by the activation of toll-like receptors (TLRs) and IL-1 receptors…
PharmaceuticalsProtein and Peptide Synthesis and Manufacturing
10 Jul 20
Mylan and Fujifilm Kyowa Kirin Biologics have been working under the partnership since 2018 for the commercialisation of…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
09 Jul 20
Lynparza is an advanced PARP inhibitor and a targeted treatment designed to block the DNA damage response (DDR)…
08 Jul 20
The approval indicated the drug for uncontrolled asthma in patients who experienced one or more asthma exacerbations in…
06 Jul 20
Cabotegravir plus rilpivirine is an investigational regimen indicted for the treatment of HIV-1 infection in patients who are…
06 Jul 20
The conditional marketing authorisation was granted based on the US National Institute of Allergy and Infectious Diseases’ global…
03 Jul 20
In the Phase 3 BRIGHTE trial, 60% of heavily treatment-experienced adults receiving Rukobia with an optimised background therapy…
03 Jul 20
The EC approval is based on the Phase 3 CREDENCE trial, which was stopped early after a planned…
02 Jul 20
Novartis has reached a settlement with the US Attorney’s Office for the Southern District of New York, the…
02 Jul 20
The Ebola vaccine regimen has been developed by leveraging Janssen’s AdVac technology, and Bavarian Nordic’s MVA-BN technology